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Background: A worldwide poliomyelitis eradication program was initiated in 1988; however, strains of wild
poliovirus (WPV) are still endemic in some countries. Until WPV transmission is eradicated globally, importation and
outbreaks of WPV are alarming possibilities. This study is the first report to document the polio immunity after 2004,
when an inactivated polio vaccine (IPV) was introduced in the Republic of Korea.
Methods: A total of 745 serum samples from randomly selected patients ranging from 6 to 84 years of age were
used for neutralization tests, performed in the World Health Organization polio national reference laboratory.
Results: Among the 745 tested sera, 439 (58.9%) were seropositive and 19 (2.6%) were seronegative to all PV
serotypes. In all age groups, PV3 showed the lowest level of seroprevalence, at 509 cases (68.3%), compared to
616 (82.7%) for PV1 and 685 (91.9%) for PV2. In the 6–10-year age group, which included IPV-immunized children,
the highest seropositive rate was observed and the difference in seroprevalence between PV3 and other serotypes
was the lowest compared to the other age groups immunized with oral PV vaccines (OPV). In addition, the
seronegative rates of all three PV types in children aged 6–10 in this study were found to be lower than those in
OPV-immunized children reported in a previous study from the Republic of Korea. Meanwhile, middle-aged subjects
(41–60 years) had the lowest seroprevalence and geometric mean titer.
Conclusions: This study indicates a deficiency in immunity to PV in middle-aged individuals, and low seroprevalence
to PV3 in all age groups. In addition, due to the ongoing risk of importing PV, middle-aged people should consider
PV vaccination before visiting a PV-endemic country. Our findings provide data to assist those involved in deciding
future national polio vaccination strategies for the maintenance of a polio-free status in Korea.
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Poliovirus (PV) is a member of the Picornaviridae family
and is classified as a human enterovirus-C species of the
genus Enterovirus [1,2]. PV can be divided into 3 different
serotypes, PV1, PV2, and PV3, and can cause poliomyelitis
and other neurologic disorders, as might be found with
serious infectious diseases, and can cause permanent re-
sidual paralysis. PV is transmitted primarily through the
fecal-oral route and can cause viremia following replica-
tion in the gastrointestinal tract [3,4]. Occasionally, PV
invades the central nervous system and destroys lower
motor neurons, causing a clinically distinctive flaccid
paralysis [5].
Efforts to eradicate PV through a World Health
Organization (WHO) vaccination program were initiated
in 1988 [5], and eradication was achieved through inten-
sive immunization and attentive surveillance [6]. However,
wild PV (WPV) 1 and WPV3 are still currently endemic
in 3 countries (Afghanistan, Nigeria, and Pakistan), with
diminished chains of transmission, while WPV2 was erad-
icated in 1999 [7,8]. Therefore, despite the intensive ef-
forts in eradicating PV, PV-free countries remain at risk of
WPV importation. For example, in 2011, a strain of
WPV1 that was genetically linked to a virus currently cir-
culating in Pakistan was isolated in China, where the last
indigenous poliomyelitis case had occurred in 1994 [9].
This transmission indicated that WPV remains a risk for
all countries until it is completely eradicated globally.
In addition, in May 2014, the WHO declared an emer-
gency regarding the spread of WPV, based on recom-
mendations on the international spread of PV; thus,
travelers are now urged to undergo PV vaccination if
they intend to travel to endemic areas [http://www.
polioeradication.org/Portals/0/Document/Emergency/
PolioPHEICguidance.pdf]. Until WPV is eradicated
globally, its importation and outbreaks will continue in
countries that share borders with WPV-endemic coun-
tries, and adequate vaccination strategies are therefore
essential in establishing protection against PV.
The Western-pacific region, including the Republic of
Korea, was declared WPV-free in 2000. The oral PV vac-
cine (OPV), which contains the Sabin PV1, PV2, and PV3
strains, was introduced to the Republic of Korea in the
early 1970s and included in the national immunization
program [10]; at the end of 2004, it was replaced with the
inactivated PV vaccine (IPV), which includes formalin-
inactivated the Mahoney strain of PV1, the MEF-1
strain of PV2, and the Saukett strain of PV3 [7,10,11].
The immunization of PV is given three times to all in-
fants at 2, 4, and 6–18 months of age, followed by a
booster shot before school entry at between 4 and 6
years of age [10]. The immunization level for PV has
been sustained at an estimated 90–95% since 1980 [12];
however, the seroprevalence of anti-PV antibodies hasnot been investigated in the Republic of Korea since the
introduction of the IPV. Therefore, this study was de-
signed to estimate the level of immunity against PV1,
PV2, and PV3 in broad age groups, ranging from 6 to 84
years of age, in the Republic of Korea.
Methods
Study design
This study evaluated the seroprevalence of PV1, PV2, and
PV3 antibodies, and the vaccination coverage in 745
serum samples selected from participants in regions
throughout the Republic of Korea. The serum samples
were collected from the study subjects between April and
November 2012. Individuals who randomly attended hos-
pitals for a blood test due to reasons not related to PV
immunization were enlisted in the study, although the
immunization history of the individuals was not available.
Approximately 2 mL of blood was collected, allowed
to clot, and centrifuged, and the serum was aspirated
into a sterile cryovial. Subsequently, the serum samples
were transported to the WHO polio national reference
laboratory of the Korea Centers for Disease Control and
Prevention for analysis. All sera were stored at -20°C
until tested. Before testing, each serum sample was inac-
tivated at 56°C for 30 min.
Participant information (sex, age, and region) was col-
lected. On enrollment, the subjects (range: 6–84 years of
age) were stratified into five age groups: 6–10, 11–20,
21–40, 41–60, and >60 years. Seroprevalence was com-
pared between the different groups in terms of sex, age,
and region.
Neutralization tests
Neutralization tests were performed using Sabin PV1,
PV2, and PV3 strains and a rhabdomyosarcoma (RD)
cell line according to the WHO manual [13]. The PV ref-
erence strains used in this study were 01/528 (Sabin I),
01/530 (Sabin II), and 01/532 (Sabin III), which were ob-
tained from the WHO. The titers of neutralizing anti-
bodies against PV1, PV2, and PV3 were determined using
the micro neutralization assay [13]. The sera were inacti-
vated at 56°C for 30 min and subsequently diluted from
1:4 to 1:2,048 in two-fold serial dilutions (final volume,
50 μl), in duplicate, and each dilution was incubated for
1 h at 36°C to allow the antibodies to bind to PV (100
TCID50). Next, the RD cell suspensions (1 × 10
5 cells)
were added to the virus-serum mixtures in 96-well
plates. Virus and cell controls were included for com-
parison. The plates were incubated at 36°C and exam-
ined daily for 5 days for proof of cytopathic effect. Based
on the WHO recommendations, serum with a titer of
more than 1:8 was considered positive [14]. According
to the previously defined standard [15,16], low, medium,
and high immunity to PV1, PV2, and PV3 were defined
Kim et al. BMC Infectious Diseases  (2015) 15:164 Page 3 of 7as titers between 1:8–1:32, 1:64–1:256, and >1:512,
respectively. The seroprotection rates and geometric
mean titers (GMTs) of antibodies were calculated for
each serotype in each age group.
Data analysis
The GMTs (95% confidence intervals) for PV1, PV2, and
PV3 antibodies among the groups were calculated. Statis-
tical analysis was performed using SPSS version 15.0 (SPSS,
Inc., Chicago, IL), with P-values < 0.05 considered statisti-
cally significant. Statistical significance was calculated using
Chi-square test and linear-by-linear association.
Ethics approval
The institutional review board of Korea Centers for Dis-
ease Control and Prevention approved the use of the sam-
ples (number: 2012-08EXP-07-R), and all patients provided
written informed consent before enrolling in this study.
Results
Study population
Of the 745 subjects, 349 (46.8%) were male and 396
(53.2%) were female, with a male-to-female ratio of 1:1.13.
On enrollment, the subjects were stratified into 5 age







Total 745 616 (82.7)
Sex
Male 349 (46.8) 289 (82.8) 0.51
Female 396 (53.2) 327 (82.6)
Age (years)
6–10 (IPV) 236 (31.7) 220 (93.2) <0.01
11–20 (OPV) 216 (29.0) 173 (80.1)
21–40 (OPV) 135 (18.1) 106 (78.5)
41–60 (OPV) 113 (15.2) 79 (69.9)
>60 (OPV) 45 (6.0) 38 (84.4)
Region
Gyeonggi-do 237 (31.8) 202 (85.2) 0.065
Gyeongsang-do 170 (22.8) 135 (79.4)
Seoul 126 (16.9) 103 (81.7)
Chungcheong-do 112 (15.0) 95 (84.8)
Jeolla-do 68 (9.1) 54 (79.4)
Gangwon-do 24 (3.2) 19 (79.2)
Jeju-do 8 (1.1) 8 (100.0)
*P < 0.05 indicates significant differences of seroprevalence among the compared g
IPV, inactivated poliovirus vaccine; OPV, oral poliovirus vaccine; PV, poliovirus.21–40 (n = 135; 18.1%), 41–60 (n =113; 15.2%), and >60
years (n = 45; 6.0%).
The geographical distribution of the study population
was further analyzed according to the regions of Korea:
Gyeonggi-do (n = 237; 31.8%), Gyeongsang-do (n = 170;
22.8%), Seoul (n = 126; 16.9%), Chungcheong-do (v = 112;
15.0%), Jeolla-do (n = 68; 9.1%), Gangwon-do (n = 24; 3.2%),
and Jeju-do (n = 8; 1.1%) (Table 1).Antibody seroprevalence
A total of 439 (58.9%) subjects were seropositive, and 19
subjects (2.6%) were seronegative to all three PV types
(Figure 1). No detectable antibody was observed for 3
(0.4%), 7 (0.9%), 4 (0.5%), 5 (0.7%), and 0 patients in the
6–10, 11–20, 21–40, 41–60, and >60-year age groups,
respectively (data not shown). The number of subjects
seronegative to PV1, PV2, and PV3 were 52 (7.0%), 15
(2.0%), and 139 (18.7%), respectively. More subjects were
seronegative to both the PV1 and PV3 antibodies (7.4%)
than to both the PV2 and PV3 antibodies (3.1%) or both
the PV1 and PV2 antibodies (0.4%) (Figure 1).
The numbers of seropositive subjects were as follows:
616 (82.7%) to PV1, 685 (91.9%) to PV2, and 509 (68.3%)
to PV3. There was no significant difference in the number
of subjects seropositive to PV1 and PV3 between theo sex, age, and region (n = 745)
PV2 PV3
e* No. of positive
samples (%)
P value No. of positive
samples (%)
P value
685 (91.9) 509 (68.3)
314 (90.0) 0.04 236 (67.6) 0.38
371 (93.7) 273 (68.9)
228 (96.6) <0.05 207 (87.7) <0.01
199 (92.1) 126 (58.3)
122 (90.4) 72 (53.3)
95 (84.1) 74 (65.5)
41 (91.1) 30 (66.7)
226 (95.4) 0.018 172 (72.6) 0.033
154 (90.6) 108 (63.5)
114 (90.5) 80 (63.5)
101 (90.2) 85 (75.9)
59 (86.8) 42 (61.8)
23 (95.8) 17 (70.8)
8 (100.0) 5 (62.5)
roups.
Figure 1 The number (%) of subjects without neutralizing antibodies to one or more poliovirus (PV) types or a combination of PV1,
PV2, and PV3.
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sex difference for PV2 (P = 0.04) (Table 1).
In addition, there were significant correlations be-
tween the age groups and seropositivity. The 6–10-year
age group showed the highest levels of seropositivity to
PV1, PV2, and PV3 (93.2%, 96.6%, and 87.7%, respect-
ively), while the 40–60-year age group had the lowest
levels of seropositivity to PV1 and PV2 compared to the
other age groups, including elderly people aged >60
years. For all age groups, the seropositivity was the low-
est for PV3 and the highest for PV2. Furthermore, there
was also significant regional differences in the seropositivity
to PV2 and PV3 (P < 0.05). Jeolla-do had the lowest sero-
prevalence to both PV2 (86.8%) and PV3 (61.8%) comparedFigure 2 Levels of immunity to poliovirus (PV) 1, PV2, and PV3. Low,
1:64–1:256, and >1:512. No immunity indicates that there was no titer.with the other regions; meanwhile, Gyeonggi-do had the
highest rates of seroprevalence for PV2 (95.4%) and PV3
(72.6%) (Table 1).
Comparison of geometric mean titers
The overall levels of immunity to PV are shown in
Figure 2. The proportion of subjects with high immunity
was 10.9% for PV1, 14.5% for PV2, and 7.2% for PV3.
The corresponding proportions of medium immunity
were 32.8%, 39.3%, and 25.2%, respectively, while those for
low immunity were 39.1%, 38.1%, and 35.8%, respectively.
Finally, the proportion of subjects with no immunity was
the highest for PV3, at 31.7%, as compared to 17.3% for
PV1 and 8.1% for PV2 (Figure 2).medium, and high immunity indicate neutralizing ranges of 1:8–1:32,
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GMTs of PV1, PV2, and PV3 were 163.1, 206.2, and
108.4, respectively. The lowest level of GMT was ob-
served for PV3. Statistically significant differences in
GMT were observed between the sexes for PV1 and
PV3, and there were also significant differences in the
GMTs between the age groups for each PV type (P <
0.01). The GMT for all PV types was the highest in the
6–10-years age group compared to the other groups. InTable 2 Geometric mean titers (GMTs) of poliovirus-antibodie
PV1 PV2


































The data are presented as mean (95% confidence interval).
*P < 0.05 indicates significant differences of seroprevalence among the compared g
PV, poliovirus.particular, the GMTs of PV2 and PV3 in the 21–40-year
age group were lower than those in the other groups.
For PV1, the GMT was lower in the 41–60 years age
group than that in the other groups. Higher GMTs were
observed for PV2 than for the other PV types for all age
groups, and lower GMTs were observed for PV3 for all
age groups. For PV2 and PV3, there were statistically
significant differences in the GMTs between the different
regions, with the Chungcheong-do province having thes according to sex, age, and region
PV3
T P value GMT P value
.2 108.4
.2–238.1) (85.3–131.5)
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the lowest GMT levels for PV2 and PV3 (Table 2).
Discussion and conclusions
Although WPV has not been detected since Korea was
declared WPV-free in 2001 [12], the Korean population
could be at risk of infection through the importation of
WPV or vaccine-derived PV, similar to what has been re-
ported in England and Wales [17]. Therefore, in this study,
we evaluated the seroprevalence of neutralizing antibodies
to PV1, PV2, and PV3 in broad age groups in the Republic
of Korea. To our knowledge, this is the first report to docu-
ment the seroprevalence of antibodies against the three PV
types since the introduction of IPV in the Republic of
Korea. Since the introduction of the Sabin vaccine in 1962
and the inclusion of OPV vaccination in the National
Immunization Program in 1970, the incidence of poliomy-
elitis has dramatically declined [10]. IPV is known to be
safe and effective and to have played an important role in
the control of poliomyelitis [18]. Accordingly, the Republic
of Korea is committed to maintaining the present level of
poliomyelitis immunization, especially since the introduc-
tion of IPV at the end of 2004.
We moreover compared the PV seroprevalence in the
IPV-immunized children (6–10 years) in this study to
that in OPV-immunized children (6–11 years) in a previ-
ous study from the Republic of Korea [10] (Table 3). The
rates of full immunity to all PV types were similar, with
82.2% (411/500) of OPV-immunized children [10] and
82.6% (195/236) of IPV-immunized children (P > 0.05)
showing full immunity. However, the seronegative rates of
each PV type in IPV-immunized children were significantly
lower than the corresponding rates in OPV-immunized
children (P < 0.05), and the antibodies to PV3 were lower
than those to the other two PV types in both studies [10]
(Table 3). In addition, there were no detectable antibodies
in 3 subjects (1.3%) in IPV-immunized children, as com-
pared to in zero subjects in OPV-immunized children [10],
and this difference was statistically significant (P <0.05).
This difference could result from several mechanisms such
as different immunogenicity of vaccine type, deficiency of
host immunity in 1990s, or inappropriate storage or ad-
ministration of OPV vaccine.
The highest seroprevalence and GMTs were observed
in the 6–10-year age group in the present study. InTable 3 PV seroprevalence of IPV-immunized children compa
No. of samples (%)
All positive P
IPV-immunized children (6–10 years, n = 236) 195 (82.6%) 16
OPV-immunized children [10] (6–11 years, n = 500) 411 (82.2%) 13
P value* >0.05 <
*P < 0.05 indicates significant differences of seroprevalence among the compared g
IPV, inactivated polio vaccine; OPV, oral poliovirus vaccine; PV, poliovirus.addition, the difference in seroprevalence between PV3
and the other PV types was less here than for the other
age groups. This is likely attributable to the PV vaccin-
ation program, in which PV vaccination in the Republic
of Korea is initiated in 2-month-old babies, and boosted
before school entry before 6 years of age. In addition, those
in the 41–60-year age group had the lowest seroprotection
levels and GMTs compared to the other age groups. This
age group was born in 1950–1970, prior to the inclusion of
PV vaccination in the National Immunization Program.
Accordingly, those in the 41–60-year age group may lack
serum antibodies. Decreasing immunity to PV in older age
groups because of waning effect has also been reported in
other studies [19], and elderly age groups would appear to
be at risk of infection in the case of WPV importation [17].
However, this study indicated that the seroprotection level
and GMT of subjects >60 years were higher than those of
subjects in the 41–60-year age group, and we speculate
that humoral neutralizing antibodies to PV in subjects
aged >60 years may have been enhanced by a memory B
cell immune response from a natural infection.
Differences in the population susceptibility or clinical
symptoms of poliomyelitis between different age groups
have not been described; however, several polio outbreaks
affecting adults in WPV-free countries have been previously
reported, while poliomyelitis is rarely observed in adults in
such countries [20-22]. The older age groups may contribute
to WPV transmission without clinical symptoms, and the
WHO has therefore recommended older individuals
to get vaccinated as part of the outbreak response
[http://www.polioeradication.org/Portals/0/Document/
Emergency/PolioPHEICguidance.pdf].
WPV2 has been eradicated worldwide, and has not
been detected since the last case in India in 1999 [23].
On the other hand, PV1 and PV3 are currently endemic
in several countries in Africa and Asia, with the most
recent WPV3 isolated in November 2012 [http://www.
polioeradication.org/Portals/0/Document/StrategicPlan/
StratPlan2010_2012_ENG.pdf]. In this study, the im-
munity levels were the highest for PV2 and lowest for
PV3 for all age groups. The high immunogenicity to PV2
could be attributed to the early PV2 eradication. Con-
versely, the deficiency in immunity to PV3 has previously
been described in several studies [16,24-27]; it may be ex-
plained by a lower potency of PV3 antigens in the vaccine;red to OPV-immunized children in a previous study [10]
V1-negative PV2-negative PV3-negative All negative
(2.6%) 8 (1.0%) 29 (7.5%) 3 (1.3%)
(6.8%) 5 (3.4%) 38 (12.3%) 0 (0%)
0.01 <0.05 <0.05 <0.05
roups.
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immunity.
In conclusion, the results of the present study suggest
that the PV3 component of the PV vaccine should be
further evaluated. In addition, the danger of WPV infec-
tion has not been completely averted, and PV vaccin-
ation strategies are absolutely necessary to preserve our
present PV-free status. In particular, due to the ongoing
risk of importable PV, if middle-aged people are travel-
ling to PV-endemic countries, they should be urged to
consider PV vaccination. Our findings provide data to
assist those involved in deciding future national PV vac-
cination strategies to maintain a poliovirus-free status.
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